Patent ID: 9555099
Date: 2017-01-31
CPC Classifications: A61K,A61P,C07K,C12N

Claim:
1. A trivalent immunogenic composition comprising: (a) an immunogenic fragment of an Herpes Simplex virus type 2 (HSV-2) UL19 polypeptide wherein the immunogenic fragment of UL19 has the amino acid sequence set forth in SEQ ID NO: 12, and wherein the immunogenic fragment lacks at least 75% of amino acids 1-450 of SEQ ID NO: 4 and lacks at least 75% of amino acids of 1055-1374 of SEQ ID NO: 4; or an immunogenic variant thereof that retains at least 90% amino acid identity over the full length of the immunogenic fragment, glycoprotein D of HSV-2 (gD2), wherein the gD2 comprises the amino acid sequence set forth in SEQ ID NO: 2 or 3, or an immunogenic fragment thereof comprising at least 15 contiguous amino acids of SEQ ID NO: 2 or 3, and UL25, wherein the UL25 comprises the amino acid sequence set forth in SEQ ID NO: 5 or an immunogenic fragment thereof comprising at least 15 contiguous amino acids of SEQ ID NO: 5; (b) an amount of Glucopyranosyl Lipid Adjuvant (GLA) that increases the immune response; and (c) a pharmaceutically acceptable carrier.